Scilex and Oracle: Bullish Views, Potential Upsides Unveiled
- October 09th, 2023
- 683 views
HC Wainwright & Co. has initiated coverage on Scilex Holding Company (Nasdaq: SCLX), a pharmaceutical company, with a Buy rating and a price target of $12.
Closing at $1.57 on Friday, this price target suggests a substantial potential upside of $10.43 per share or approximately 664.33% for $SCLX, based on the financial services firm's view.
Separately, Evercore ISI Group upgraded Oracle Corporation (NYSE: ORCL), a multinational technology company, from In-Line to Outperform and raised the price target from $131 to $135.
With $ORCL closing at $109.96 on Friday, the projected new price target implies a potential upside of $25.04 per share or about 22.77%, according to the investment banking advisory firm's assessment.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login